JRSM Cardiovascular Disease最新文献_第9页

Autophagy in the heart is enhanced and independent of disease progression in mus musculus dystrophinopathy models 在肌营养不良模型中，心脏的自噬增强且独立于疾病进展

IF 1.6

JRSM Cardiovascular Disease Pub Date : 2019-01-01 DOI: 10.1177/2048004019879581

H. Spaulding, C. Ballmann, J. Quindry, M. Hudson, J. Selsby

{"title":"Autophagy in the heart is enhanced and independent of disease progression in mus musculus dystrophinopathy models","authors":"H. Spaulding, C. Ballmann, J. Quindry, M. Hudson, J. Selsby","doi":"10.1177/2048004019879581","DOIUrl":"https://doi.org/10.1177/2048004019879581","url":null,"abstract":"Background Duchenne muscular dystrophy is a muscle wasting disease caused by dystrophin gene mutations resulting in dysfunctional dystrophin protein. Autophagy, a proteolytic process, is impaired in dystrophic skeletal muscle though little is known about the effect of dystrophin deficiency on autophagy in cardiac muscle. We hypothesized that with disease progression autophagy would become increasingly dysfunctional based upon indirect autophagic markers. Methods Markers of autophagy were measured by western blot in 7-week-old and 17-month-old control (C57) and dystrophic (mdx) hearts. Results Counter to our hypothesis, markers of autophagy were similar between groups. Given these surprising results, two independent experiments were conducted using 14-month-old mdx mice or 10-month-old mdx/Utrn± mice, a more severe model of Duchenne muscular dystrophy. Data from these animals suggest increased autophagosome degradation. Conclusion Together these data suggest that autophagy is not impaired in the dystrophic myocardium as it is in dystrophic skeletal muscle and that disease progression and related injury is independent of autophagic dysfunction.","PeriodicalId":30457,"journal":{"name":"JRSM Cardiovascular Disease","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/2048004019879581","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42351854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Cardiovascular disease in transgendered people: A review of the literature and discussion of risk 变性人的心血管疾病:文献综述和风险讨论

IF 1.6

JRSM Cardiovascular Disease Pub Date : 2019-01-01 DOI: 10.1177/2048004019880745

L. Seal

{"title":"Cardiovascular disease in transgendered people: A review of the literature and discussion of risk","authors":"L. Seal","doi":"10.1177/2048004019880745","DOIUrl":"https://doi.org/10.1177/2048004019880745","url":null,"abstract":"This review examines the impact of gender affirming hormone therapy used in the transgendered and non-binary populations on cardiovascular outcomes and surrogate markers of cardiovascular health. Current evidence suggests that hormonal therapy for transgendered women decreases or is neutral regarding myocardial infarction risk. There is an increased incidence of venous thromboembolism (VTE), but newer studies suggest that the risk is significantly lower than previously described. For transgendered men, there appears to be an adverse effect on lipid parameters but this does not translate into an increased risk of cardiovascular disease above that of general male population. In all transgendered people, risk factor interventions such as smoking cessation, weight management and treatment of co-morbid conditions are important in optimising cardiovascular health. The effect of gender affirming hormonal therapy in transgendered people is difficult to interpret due to the variety of hormone regimens used, the relative brevity of the periods of observation and the influence of confounding factors such as the historical use of less physiological, oestrogens such as conjugated equine oestrogen and ethinylestradiol which are more pro-thrombotic than the 17β oestradiol that is used in modern practice.","PeriodicalId":30457,"journal":{"name":"JRSM Cardiovascular Disease","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/2048004019880745","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48919827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 28

Thanks to Reviewer List 感谢Reviewer List

IF 1.6

JRSM Cardiovascular Disease Pub Date : 2019-01-01 DOI: 10.1177/2048004019857391

引用次数: 0

Percutaneous treatments of acute myocardial infarction and major stroke: Two parallel roads 急性心肌梗死与脑卒中的经皮治疗:两条平行的道路

IF 1.6

JRSM Cardiovascular Disease Pub Date : 2019-01-01 DOI: 10.1177/2048004019869162

G. Vizzari, F. Versaci, A. Nicosia

引用次数: 0

Lipid‐Related Factors 脂质量相关因素

IF 1.6

JRSM Cardiovascular Disease Pub Date : 2018-12-28 DOI: 10.1002/9781118829875.ch4

引用次数: 0

Inflammation‐Related Factors 炎症所致相关因素

IF 1.6

JRSM Cardiovascular Disease Pub Date : 2018-12-28 DOI: 10.1002/9781118829875.ch5

P. Yaqoob, G. Ferns

引用次数: 0

The Haemostatic System 止血系统

IF 1.6

JRSM Cardiovascular Disease Pub Date : 2018-12-28 DOI: 10.1002/9781118829875.ch8

引用次数: 0

Obesity, Metabolic Syndrome and Type 2 Diabetes 肥胖、代谢综合征和2型糖尿病

IF 1.6

JRSM Cardiovascular Disease Pub Date : 2018-12-28 DOI: 10.1007/978-1-4471-4619-3_53

J. Steinberger, A. Kelly

引用次数: 9

Influences of the Human Gut Microbiome 人类肠道微生物组的影响

IF 1.6

JRSM Cardiovascular Disease Pub Date : 2018-12-28 DOI: 10.1002/9781118829875.ch11

引用次数: 0

Endothelial and Vascular Function 内皮和血管功能

IF 1.6

JRSM Cardiovascular Disease Pub Date : 2018-12-28 DOI: 10.1002/9781118829875.ch7

引用次数: 0